Report

The Alarmin Interleukin-33 Drives Protective Antiviral CD8+ T Cell Responses

See allHide authors and affiliations

Science  24 Feb 2012:
Vol. 335, Issue 6071, pp. 984-989
DOI: 10.1126/science.1215418

Abstract

Pathogen-associated molecular patterns decisively influence antiviral immune responses, whereas the contribution of endogenous signals of tissue damage, also known as damage-associated molecular patterns or alarmins, remains ill defined. We show that interleukin-33 (IL-33), an alarmin released from necrotic cells, is necessary for potent CD8+ T cell (CTL) responses to replicating, prototypic RNA and DNA viruses in mice. IL-33 signaled through its receptor on activated CTLs, enhanced clonal expansion in a CTL-intrinsic fashion, determined plurifunctional effector cell differentiation, and was necessary for virus control. Moreover, recombinant IL-33 augmented vaccine-induced CTL responses. Radio-resistant cells of the splenic T cell zone produced IL-33, and efficient CTL responses required IL-33 from radio-resistant cells but not from hematopoietic cells. Thus, alarmin release by radio-resistant cells orchestrates protective antiviral CTL responses.

Pathogen-associated molecular patterns (PAMPs) characterize intruding microorganisms and are important for adaptive immune responses to viral infection (1). Conversely, endogenous molecular patterns, which indicate tissue injury, are referred to as alarmins and form a second class of damage-associated molecular patterns (DAMPs) (2). Unlike PAMPs, the potential contribution of alarmins to antiviral immune defense remains largely elusive.

Many viruses are excellent inducers of cytotoxic CD8+ T lymphocytes (CTLs) (3), the basis of which is incompletely understood. To screen for inflammatory signals augmenting antiviral CTL responses, we used lymphocytic choriomeningitis virus (LCMV) infection of mice. We performed a genome-wide cDNA expression analysis of total spleen tissue from LCMV-infected mice and compared it to an analysis of uninfected controls. From a large panel of interleukins and pro-inflammatory cytokines, interferon-γ (IFN-γ) and IL-33 were most up-regulated (table S1). The IL-33 receptor ST2, an IL-1 receptor family member also known as T1 and IL1RL1, was also up-regulated.

IL-33 is expressed in the nucleus of nonhematopoietic cells, such as fibroblasts and epithelial and endothelial cells of various tissues (4), but its role in antiviral CTL responses is unknown. Its bioactive pro-inflammatory form is released as a result of necrosis but not apoptosis, classifying IL-33 as an alarmin (57). IL-33 mRNA expression peaked at 3 to 5 days after infection and grossly paralleled the kinetics of LCMV RNA (Fig. 1A). To test whether IL-33 was important for CTL responses to LCMV, we performed infection experiments in IL-33–deficient (Il33−/−) mice (8). Absence of IL-33 reduced the absolute number of CTLs responding to the immunodominant LCMV epitope GP33 by >90%. The frequency of epitope-specific CTLs was reduced by >75% (Fig. 1B). When expressed as a nuclear factor in healthy cells, IL-33 is complexed with chromatin and modulates gene expression (9). Upon release from necrotic cells, however, IL-33 binds and signals through ST2 (10, 11). To assess which one of these roles of IL-33 accounted for defective CTL responses in Il33−/− mice, we used transgenic mice expressing a soluble decoy receptor for IL-33 [Il1rl1-Fc mice (12)]. Il1rl1-Fc mice displayed defective CTL expansion analogously to Il33−/− mice (fig. S1A). Mice lacking the IL-33 receptor ST2 [Il1rl1−/− (13)] also mounted similarly reduced responses to all three LCMV epitopes tested (Fig. 1C and fig. S1, B and C). This indicated that IL-33 was released to the extracellular compartment and signaled through ST2 to amplify antiviral CTL responses.

Fig. 1

The IL-33–ST2 pathway drives protective CTL responses to replicating viral infection. (A) Kinetic analysis of IL-33 and LCMV RNA expression in the spleen after LCMV infection. Symbols represent the mean ± SEM of four mice. N = 1 (N refers to the number of times an experiment was performed). (B and C) The number of GP33-specific CTLs in the spleen, as detected by peptide–major histocompatibility complex (MHC) tetramer staining, on day 8 after LCMV infection. Bars represent mean ± SEM of five mice. N = 1 (B) or 3 (C). (D) Epitope-specific CTLs of WT and Il1rl1−/− mice responding to replicating WT LCMV infection or to replication-deficient rLCMV vectors. Bars represent the mean ± SEM of five mice. N = 2. P < 0.0001 by one-way analysis of variance (ANOVA). Results of Bonferroni’s posttest are indicated. n.s., not significant; *P < 0.05; **P < 0.01. (E and F) WT mice were vaccinated with recombinant VV vector expressing LCMV-GP (E) or with GP33-carrying VLPs (F) on day 0 and were treated with IL-33 or diluent [phosphate-buffered saline (PBS)] daily from day 1 to 7, and CTL responses were determined on day 8. Bars represent the mean ± SEM of four to five mice. N = 2 (E) or 1 (F). (G) Viremia after infection with 2 × 106 plaque-forming units (PFU) of LCMV-WE. Symbols represent the mean ± SEM of five mice. N = 2. (H) Splenic MHV-68 titers on day 10 after infection. Bars represent the mean ± SEM of five mice. N = 1. (I) Pulmonary VV titers on day 8 after infection. Bars represent the mean ± SEM of four to five mice. N = 1. (J) Incidence of choriomeningitis after intracerebral LCMV infection. Terminally diseased animals were killed in accordance with Swiss law. Survival was compared by using the log rank test. Groups of six mice were used. One of two similar experiments is shown. Unpaired two-tailed student’s t test was used for statistical analysis in (B), (C), (E), (F), (H), and (I).

Analogous to the responses against LCMV, an RNA virus, Il1rl1−/− mice also exhibited significantly reduced CTL responses against murine γ-herpesvirus 68 [MHV-68 (14)], a DNA virus (fig. S1D). In further analogy to LCMV, MHV-68 induced IL-33 mRNA up-regulation (fig. S1E). The differences in CTL responses to LCMV and MHV-68 were also reflected in reduced antigen-specific cytotoxicity (fig. S1, F and G). However, CTL responses to a nonreplicating adenovirus-based vaccine vector were similar in Il1rl1−/− and wild-type (WT) mice (fig. S1H).

Given IL-33 can act as an alarmin, we hypothesized that productive viral replication may represent a unifying characteristic of LCMV and MHV-68 infection, differentiating them from adenoviral vectors. Indeed, the CTL responses of WT and Il1rl1−/− mice to replication-deficient LCMV-based vaccine vector (15) were indistinguishable, and the magnitude of these responses was comparable to the magnitude of responses observed in WT LCMV-infected Il1rl1−/− mice (Fig. 1D). Further, Il1rl1−/− mice mounted defective CTL responses against WT vaccinia virus (VV), whereas attenuated [thymidine kinase–deficient (16)] VV-based vectors induced comparable responses in Il1rl1−/− and WT controls (fig. S1I). Thus, we hypothesized that exogenously administered IL-33 could mimic viral replication to enhance vaccine-induced CTL responses. Indeed, recombinant IL-33 significantly augmented CTL responses to VV-based vectors and viruslike particles (VLPs) (Fig. 1, E and F).

CTLs play a pivotal role in the resolution of primary viral infection (14, 17). Il1rl1−/− mice controlled low-dose LCMV infection (fig. S1J) but displayed elevated viremia after high-dose LCMV infection and often progressed to viral persistence, whereas WT control mice eliminated the virus (Fig. 1G and fig. S1K). ST2-deficient mice also displayed a log increase in splenic MHV-68 titers and three logs increase in pulmonary VV titers (Fig. 1, H and I). LCMV-neutralizing antibody responses were comparable in Il1rl1−/− mice and WT controls (fig. S1L), suggesting that defective CTL responses of Il1rl1−/− mice were at the root of impaired LCMV control.

LCMV can cause lethal CTL-mediated immunopathologic disease of the central nervous system when administered intracranially (17). Five out of six WT mice developed terminal disease within 10 days, whereas all Il1rl1−/− mice survived without clinical signs of immunopathology (Fig. 1J).

The IL-33 receptor ST2 has predominantly been detected on mast cells and CD4+ T helper type 2 cells (1820), reportedly exerting pleiotropic effects on helminth-specific immunity, allergy, anaphylaxis, autoimmune, and cardiovascular disease (20, 21). Conversely, ST2 expression on human and mouse CTLs has only recently been found under select in vitro culture and differentiation conditions (22). Hence, we investigated which cells were sensing IL-33 for augmenting antiviral CTL responses. To this end, we reconstituted lethally irradiated mice with an approximately 1:1 mixture of WT (CD45.1+) and ST2-deficient bone marrow (CD45.1) (Fig. 2A and fig. S2A). Compared with uninfected mice, WT cells were 10-fold overrepresented in the population of antigen-specific CTLs responding to LCMV infection (Fig. 2A). In contrast, the repartition of WT and Il1rl1−/− B cells remained unaltered (fig. S2A). These observations suggested that virus-reactive CTLs respond to IL-33 directly. Independent evidence was obtained when T cell receptor–transgenic GP33-specific CTLs (23) (P14 cells) were adoptively transferred, followed by LCMV challenge (Fig. 2B). Impaired expansion of ST2-deficient P14 cells in WT recipients corroborated CTL-intrinsic ST2 signaling. As expected, no such differences were seen between control and ST2-deficient P14 cells in the IL-33–depleted environment of Il1rl1-Fc mice (Fig. 2B). Primary CTL responses to LCMV are CD4 T cell independent (24), and the differences in CTL responses between WT and Il1rl1−/− mice persisted when CD4+ T cells were depleted (fig. S2B). Altogether, these findings established a CTL-intrinsic role of ST2 signaling in the expansion of antiviral CTLs.

Fig. 2

CD8+ T cell–intrinsic signaling through ST2 and MyD88 augments antiviral CTL responses. (A) Irradiated recipients were reconstituted with WT (CD45.1+) and Il1rl1−/− (CD45.1) bone marrow. Flow cytometric analysis of WT and Il1rl1−/− total CD8+ T cells before infection (left) and virus-specific CD8+ T cells 8 days after LCMV challenge (right). Values represent mean frequency ± SEM of three mice. N = 2. (B) Control (CD45.1+CD45.2) and Il1rl1−/− (CD45.1+CD45.2+) P14 CD8+ T cells (104) were cotransferred into WT and Il1rl1-Fc recipient mice (CD45.1CD45.2+) and were enumerated on day 8 after LCMV. Bars represent the mean ± SEM of four mice per group. P < 0.0001 by one-way ANOVA. Results of Bonferroni’s posttest are indicated. One representative of three similar experiments is shown. (C) Control and Il1rl1−/− P14 cells (104) were individually transferred into WT recipients (left). Peptide-MHC tetramer–binding cells in WT and Il1rl1−/− mice were studied (right). On day 6 after LCMV infection, the indicated cell populations in spleen were analyzed for ST2 expression by flow cytometry. Values represent the mean ± SD of three mice. N = 2. (D) Flow cytometric analysis of splenic CD62LlowCD8+ T cells over time after LCMV infection. Symbols represent the mean ± SEM of three mice (WT days 2 to 8; Il1rl1−/− day 6) or the mean of two mice (other symbols). N = 2. (E) Quantitative reverse-transcription polymerase chain reaction (qRT-PCR) analysis of ST2 mRNA levels in P14 CD8+ T cells. Day 6 and 8 values represent the mean ± SEM of three mice. RNA samples from three donor mice were pooled for combined analysis on days 0 and 4. N = 1. (F and G) Flow cytometric analysis of intracellular phospho-p38 expression in control and Il1rl1−/− P14 cells isolated on day 6 (F) or over time after LCMV infection and treated ex vivo with recombinant IL-33. Symbols in (G) represent the mean ± SEM of three mice. Unpaired two-tailed student’s t test was used for statistical analysis. One representative of two similar experiments is shown. (H) Control (CD45.1+CD45.2) and Myd88−/− (CD45.1+CD45.2+) P14 cells were cotransferred to WT and Il1rl1-Fc recipient mice (CD45.1CD45.2+). Expansion was assessed 8 days after LCMV infection. Bars represent the mean ± SEM of four mice per group. P = 0.0008 by one-way ANOVA. Results of Bonferroni’s posttest are indicated. N = 1.

On day 6 after LCMV infection, we observed ST2 expression on up to 20% of virus-specific CTLs, representing the peak of expression as monitored on activated (CD62Llow) CTLs (Fig. 2, C and D, and fig. S2, C and D). In P14 cells, we detected a simultaneous peak of ST2 mRNA (Fig. 2E). IL-33 signaling through ST2 involves the adaptor protein MyD88 and downstream phosphorylation of p38 mitogen-activated protein kinase (10). Exposure of day 6 LCMV-infected splenocytes to IL-33 ex vivo increased phospho-p38 levels in control P14 cells but not in ST2-deficient ones (Fig. 2F). In concordance with induction of ST2 expression upon activation, IL-33 failed to trigger detectable phospho-p38 signals in naïve P14 cells but did so on day 6 and 8 after infection (Fig. 2G). MyD88 serves important CTL-intrinsic functions, but the upstream receptor(s) accounting for these effects had remained elusive (25). In agreement with previous reports, Myd88−/− P14 cells expanded significantly less than control P14 cells when adoptively transferred into WT recipients and challenged with LCMV (Fig. 2H). In the IL-33–depleted environment of Il1rl1-Fc recipients, however, control and Myd88−/− P14 cells responded equivalently, suggesting that defective expansion of Myd88−/− P14 cells was largely attributable to a lack of ST2 downstream signaling.

CTL functionality represents an important correlate of protective capacity (26). A substantial proportion of control P14 effector cells were plurifunctional, co-expressing IFN-γ, tumor necrosis factor (TNF)-α, IL-2, and the degranulation marker CD107a in various combinations (Fig. 3A). Conversely, about 95% of ST2-deficient P14 cells were monofunctional or lacked effector function (Fig. 3A). Reduced plurifunctionality was also observed in polyclonal antiviral CTL populations of ST2-deficient compared with WT mice (fig. S3A). Coexpression of granzyme B and CD107a indicates efficient cytotoxicity and was nearly undetectable in ST2-deficient P14 cells (Fig. 3B). Control P14 cells also contained significantly higher levels of the anti-apoptotic protein Bcl-2 than ST2-deficient cells (Fig. 3C).

Fig. 3

Broad and profound influence of ST2 signaling on effector CTL differentiation and functionality. (A to C) CD45.1+ control and ST2-deficient P14 CD8+ T cells (104) were adoptively transferred into WT recipient mice, which were then challenged with LCMV. Cytokine profile (A), cytolytic phenotype (B), and Bcl-2 expression (C) were assessed on day 8 after LCMV infection. Bars represent mean ± SEM of three mice. Values in (C) represent geometric mean indices (mean ± SD of three mice per group). N = 1 [(A) and (B)] or 2 (C). (D) Gene expression profile of P14 cells from recipients as in (A) to (C). The full set of differentially expressed genes is displayed in fig. S3B (also listed in table S2). We validated select genes by qRT-PCR. Symbols show individual mice. N = 1. (E and F) Phenotypic analysis of splenic Il1rl1−/− and control P14 CD8+ T cells from day 8 LCMV-infected WT recipients as in (A) to (C). Values indicate mean ± SD of three mice. Naïve control P14 T cells are shown as reference in (F) (gray shaded). N = 1. Unpaired two-tailed student’s t test was used for statistical analysis.

We performed genome-wide cDNA expression profiling of control and ST2-deficient effector P14 cells, yielding 63 differentially expressed candidate genes (fig. S3B and table S2). We validated differential expression of Klrb1c (NK1.1) and Clec2i, which influence effector cell differentiation and proliferation (27, 28); Ifitm1 and Ifitm3, which mediate the antiproliferative effects of IFN-γ and pro-apoptotic signals (29); and Tspan5, which affects cell proliferation, migration, and adhesion (30); thus corroborating the broad and profound effects of ST2 signals on the CD8+ effector T cell transcriptome (Fig. 3D). The gene that encodes KLRG-1, which is a marker of effector CTLs (31), was also among the gene array candidates. Indeed, ST2-deficient P14 cells and virus-specific CTLs of Il1rl1−/− mice exhibited a significant reduction in KLRG-1highCD127low effector CTLs, failed to express NK1.1, and expressed somewhat higher levels of the inhibitory receptor PD-1 (Fig. 3, E and F, and fig. S3, C to E). With transition to the memory phase, however, the size of the LCMV-specific CTL pool and the cells’ KLRG-1 expression became similar in WT and Il1rl1−/− mice, and vaccinated Il1rl1−/− mice controlled LCMV challenge infection as efficiently as WT controls (fig. S3, F and G). This supported the concept that inflammatory signals are more important for primary effector CTL responses than for memory formation (25, 32).

To characterize the cellular source of IL-33 bolstering antiviral CTL responses, we generated reciprocal bone marrow chimeras by using WT or Il33−/− mice (Fig. 4A). WT recipient mice generated significantly more LCMV-specific CTLs than Il33−/− recipients, irrespective of the IL-33 competence of the bone marrow. These data suggested that radio-resistant, and thus nonhematopoietic, cells are the main source of IL-33. IL-33+ cells were only detected in the spleen of chimeras generated from WT recipients, irrespective of the bone marrow received (WT or Il33−/−, Fig. 4B). IL-33+ cells colocalized predominantly with CD3+ cells but only sparsely with B cells (Fig. 4C and fig. S4). This was compatible with IL-33 expression by fibroblastic reticular cells (4), a stromal cell population of the T cell zone and known target of LCMV infection (33).

Fig. 4

Radio-resistant cells of the T cell zone produce IL-33 for efficient CTL induction. (A) Bone marrow chimeras were generated by using Il33−/− and WT recipients as indicated. Two months later, the CTL response to LCMV infection was determined (day 8 after infection). Bars represent the mean ± SEM of five mice. P = 0.0038 by one-way ANOVA. Results of Bonferroni’s posttest are indicated. N = 2. (B) Spleens from chimeras as in (A) were analyzed for IL-33–expressing cells by immunohistochemistry. The scale bar indicates 50 μm. The image was acquired at 100-fold magnification. Representative pictures from one out of four animals are shown. (C) IL-33+ cells (green) are predominantly found in the T cell zone (characterized by CD3+ T cell clusters, red). DAPI (4′,6′-diamidino-2-phenylindole) was used to stain nuclei (blue). The central white rectangle is displayed at higher magnification in the top left corner of the large image. The small images at right show close vicinity of IL-33+ cells and CD3+ T cells. Scale bars indicate 200 μm (large image) or 50 μm (small images and inset). Images were acquired at 200-fold magnification by using a slide scanner (large image and inset) and at 400-fold magnification by confocal microscopy (small images). Representative pictures from one out of four mice are shown.

In light of the evidence for IL-33 to act as an alarmin (5, 6), our findings offer a previously unknown molecular link to understand how viral replication, commonly thought of as “danger” (34), can enhance CTL responses to infection. The nonredundancy with PAMPs is noteworthy, particularly in the context of viral replication, which provides abundant PAMP signals (1). The observed LCMV dose dependency suggests that the IL-33–ST2 axis is most relevant under conditions of high viral burden. We identified nonhematopoietic cells in the splenic T cell zone expressing IL-33. Depending on the site of initiation and expansion of T cell responses, other cell types expressing IL-33 may also supply this cytokine to CTLs (35), and potential regulation by the soluble form of ST2 remains to be investigated (36).

PAMPs act primarily on professional antigen-presenting cells and thereby are decisive for efficient priming of CTLs (37). IL-33 and possibly also other alarmins have complementary and nonredundant functions and, in the case of IL-33, act on antiviral CTLs directly. Taken together, this study establishes a paradigm for the role of nonhematopoietic cells providing alarmins to augment and differentiate protective CTL responses to viral infection.

Supporting Online Material

www.sciencemag.org/cgi/content/full/science.1215418/DC1

Materials and Methods

Figs. S1 to S4

Tables S1 and S2

References (3840)

References and Notes

  1. Acknowledgments: This work was supported by Bundesministerium für Bildung und Forschung (BMBF)–FORSYS (A.F., M.L.), National Health and Medical Research Council (S.J.), German Research Foundation (GRK1121, A.N.H.), Science Foundation Ireland (P.G.F.), Program for Improvement of Research Environment for Young Researchers, the Special Coordination Funds for Promoting Science and Technology from the Japanese Ministry of Education, Culture, Sports, Science and Technology, Japan Science and Technology Agency, PRESTO (S.N.), BMBF (NGFNplus, FKZ PIM-01GS0802-3; H.A.), Wilhelm Sander-Stiftung (H.A.), German Research Foundation (SFB618 and SFB650, M.L.), Volkswagen Foundation (Lichtenberg Program, M.L.), Fondation Leenaards (D.D.P.), European Community (D.D.P.), and Swiss National Science Foundation (D.M., D.D.P.). We thank A. Bergthaler, G. R. Burmester, C. Gabay, M. Geuking, A. Kamath, P. H. Lambert, J. Luban, B. Marsland, G. Palmer, A. Radbruch, C. A. Siegrist, and R. M. Zinkernagel for discussions and advice; H. Saito, National Research Institute for Child Health and Development, for Il33−/− mice obtained under a materials transfer agreement (MTA) through the RIKEN Center for Developmental Biology, Laboratory for Animal Resources and Genetic Engineering; A. McKenzie (for Il1rl1−/− mice obtained under MTA); the University of Zurich (for rLCMV technology obtained under MTA) and G. Jennings [Cytos Biotechnology AG, Schlieren, Switzerland, holding patent rights on VLPs provided] for reagents; and J. Weber and B. Steer for technical assistance. The data presented in this paper are tabulated in the main paper and the supporting online material. Microarray data are deposited with National Center for Biotechnology Information Gene Expression Omnibus (GEO, accession number GSE34392) and ArrayExpress (accession number E-MTAB-901). D.D.P. is or has been a shareholder, board member, and consultant to ArenaVax AG, Switzerland, and to Hookipa Biotech GmbH, Austria, commercializing rLCMV vectors (patent application EP 07 025 099.8, coauthored by D.D.P.). The authors declare that they do not have other competing financial interests.
View Abstract

Navigate This Article